Document Detail


A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain.
MedLine Citation:
PMID:  17257473     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Determine the efficacy and tolerability of oxymorphone extended release (OPANA ER) in opioid-naive patients with moderate to severe chronic low back pain (CLBP). DESIGN AND METHODS: Patients > or = 18 years of age were titrated with oxymorphone ER (5- to 10-mg increments every 12 h, every 3-7 days) to a well-tolerated, stabilized dose. Patients were then randomized to continue their oxymorphone ER dose or receive placebo every 12 h for 12 weeks. Oxymorphone immediate release was available every 4-6 h, as needed, for the first 4 days and twice daily thereafter. RESULTS: Sixty-three percent of patients (205/325) were titrated to a stabilized dose of oxymorphone ER, most (203/205) within 1 month. During titration, 18% discontinued from adverse events (AEs) and 1% from lack of efficacy. For patients completing titration, average pain intensity decreased from 69.4 mm at screening to 22.7 mm (p < 0.0001). After randomization, 68% of oxymorphone ER and 47% of placebo patients completed 12 weeks of double-blind treatment. Approximately 8% of patients in each group discontinued because of AEs. Placebo patients discontinued significantly sooner from lack of efficacy than those receiving oxymorphone ER (p < 0.0001). Pain intensity increased significantly more in the placebo group (least squares [LS] mean change 26.9 +/- 2.4 [median 28.0]) than in the oxymorphone ER group (LS mean change 10.0 +/- 2.4 [median 2.0]; p < 0.0001). Oxymorphone ER was generally well tolerated without unexpected AEs. Although limitations of a randomized withdrawal study include the potential for unblinding and opioid withdrawal in placebo patients, opioid withdrawal was limited to two patients in the placebo group and one in the oxymorphone ER group. CONCLUSIONS: Stabilized doses of oxymorphone ER were generally safe and effective over a 12-week double-blind treatment period in opioid-naive patients with CLBP.
Authors:
Nathaniel Katz; Richard Rauck; Harry Ahdieh; Tina Ma; Roland Gerritsen van der Hoop; Rosemary Kerwin; Gilbert Podolsky
Related Documents :
6147693 - Ranitidine and cimetidine in prevention of duodenal ulcer relapse. a double-blind, rand...
6147193 - Therapeutic approaches to the common cold in children.
24450423 - Looking beyond discharge: clinical variables at trauma admission predict long term surv...
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Current medical research and opinion     Volume:  23     ISSN:  1473-4877     ISO Abbreviation:  Curr Med Res Opin     Publication Date:  2007 Jan 
Date Detail:
Created Date:  2007-01-29     Completed Date:  2007-04-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0351014     Medline TA:  Curr Med Res Opin     Country:  England    
Other Details:
Languages:  eng     Pagination:  117-28     Citation Subset:  IM    
Affiliation:
Tufts University School of Medicine, Boston, MA, USA. NKatz@analgesicresearch.com
Data Bank Information
Bank Name/Acc. No.:
ClinicalTrials.gov/NCT00225797
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Analgesics, Opioid / administration & dosage,  therapeutic use*
Analysis of Variance
Delayed-Action Preparations
Dose-Response Relationship, Drug
Double-Blind Method
Female
Humans
Low Back Pain / drug therapy*,  etiology
Male
Middle Aged
Oxymorphone / administration & dosage,  therapeutic use*
Pain Measurement
Statistics, Nonparametric
Treatment Outcome
United States
Chemical
Reg. No./Substance:
0/Analgesics, Opioid; 0/Delayed-Action Preparations; 76-41-5/Oxymorphone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Do generics offer significant savings to the UK National Health Service?
Next Document:  The when and how of insulin initiation in type 2 diabetes.